Aspire BioPharma, Inc. Financial Flexibility Index
Aspire BioPharma, Inc. financial flexibility index. Aspire BioPharma, Inc. (ASBP) has a Financial Flexibility Index of -1.19x as of June 2026. Free cash flow of $-2.12 Million (operating CF $-2.12 Million minus capex $0.00) represents -1% of total liabilities ($1.78 Million). See Aspire BioPharma, Inc. (ASBP) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Aspire BioPharma, Inc. (2021–2025)
Financial flexibility index of Aspire BioPharma, Inc. from 2021 to 2025. Historical Financial Flexibility Index trend for Aspire BioPharma, Inc. across 5 annual periods. Check Aspire BioPharma, Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Aspire BioPharma, Inc. Financial Flexibility Index by Year (2021–2025)
Aspire BioPharma, Inc. financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for Aspire BioPharma, Inc.. For the full cash flow conversion analysis, see Aspire BioPharma, Inc. (ASBP) cash conversion ratio.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.64x | $-4.92 Million | $-4.92 Million | $7.69 Million | ▼ -307.6% |
| 2024 | -0.16x | $-265.19K | $-265.19K | $1.69 Million | ▲ +90.3% |
| 2023 | -1.62x | $-653.10K | $-653.11K | $403.33K | ▼ -478.8% |
| 2022 | 0.43x | $4.75 Million | $-142.91K | $11.12 Million | ▲ +48392.3% |
| 2021 | 0.00x | $-260.00 | $-260.00 | $293.70K | — |